# Introduction oot-and-Mouth Disease Virus (FMDV) is the pathological agent of the most important diseases that affect cloven-hoofed livestock. It is a small, non-enveloped single-stranded, positive-sense RNA virus related to the family Picornaviridae. FMD has seven serotypes: O, A, C, Asia 1, and Southern African Territories (SAT) 1, 2 and 3, they cause a highly contagious disease (Alexandersen et al., 2003). There are over 60 subtypes within these serotypes. For that, there are no universal vaccines, thus presenting challenges in the selection of vaccine strains (Brown, 2003 andArzt et al., 2011). Infection with FMDV leads to an acute disease that spreads very rapidly. It characterized by fever, lameness, and vesicular lesions on the feet, tongue, snout, and teats, also characterized by high morbidity but low mortality (Grubman and Baxt, 2004). Although vaccines extensively used to control FMD, there was no antiviral therapy to treat ongoing infections with FMD virus (Grubman, 2005). The most effective FMD vaccines are consist of chemically inactivated FMDV. They can only offer complete protection after seven days of vaccination because of the time needed to trigger an immune response (Pacheco et al., 2015 andZhang et al., 2015). As oil as an adjuvants is absorbed more slowly than its gel equivalent, also can cause local reaction in the site of vaccination. To prevent such effect, can use other adjuvant types than the oil, such as nanoparticles (Batista et al., 2010). Recently nanoparticles and micro carriers are used in vaccine delivery to enhance the cellular and humeral immunity through an increased presentation of vaccine epitopes to the antigenpresenting cell (Singh et al., 2010). The particles in the nanometer size range are of particular interest may be due to their unique cellular uptake and bio-distribution properties. They also play an important role when using as vaccine antigen carriers and adjuvants (Perni et al., 2014). Silver nanoparticles (AgNPs) have attracted significant interest among the emerging Nano products because of their unique properties and increasing use for various applications in nanomedicine (Gurunathan et al., 2009). The adjuvanticity effect of AgNPs on rabies vaccine potency shown for the first time, and the results clearly showed the effect of AgNPs on increasing the humoral response to the rabies vaccine (Vahid et al., 2016). The immunological adjuvant effect of AgNPs investigated both in vitro and in vivo. The in vivo adjuvant effect of AgNPs evaluated with model antigen ovalbumin (OVA) and bovine serum albumin (BSA) in mice by intraperitoneal and subcutaneous immunization and the results showed the remarkable adjuvant effect of AgNPs. The result is beneficial for the future applications, especially in biomedicine (Xu et al., 2013). This study was carried out to determine the adjuvant effects of Silver nitrate nanoparticles when used as an adjuvant to improve the polyvalent FMD vaccine on the immune response of calves. # II. Material and Methods # Cell culture Cell line of Baby Hamster Kidney (BHK21) clone 13 was maintained in the Department of Foot and Mouth Disease Vaccine Research (DFMDVR), Veterinary Serum and Vaccine Research Institute (VSVRI), Abbasia, Cairo, according to the technique described by Macpherson and Stocher (1962), used for virus propagation and application of serum neutralization test. Using Eagle's medium with 8-10% sterile new-born calf serum obtained from Sigma, USA. # Virus propagation and concentration FMD viruses O / PanAsia2, A/Iran 05, SAT2/VII/Lib-12 (SAT2/ Lib) and SAT2/VII/Ghb-12(SAT2/Ghb) are locally isolated strains of cattle origin. The viruses were typed at VSVRI and confirmed by Pirbright, International Reference Laboratories, United Kingdom and propagated on BHK cells then concentrated using polyethylene glycol 6000 (PEG-6000) according to Killington et al.(1996) and Hiam and Eman (2010). The viral suspension was concentrated at 25,000 rpm for 5 hours at 4? in a high-speed centrifuge (Avanti J25, Beckman Coulter, and Fullerton, CA, USA). The virus in the bottom was removed and polled. It was further concentrated in an ultracentrifuge at 35,000 rpm /min for 3 hours at 4?. The viral pelted was polled and preserved at -80? to be used in vaccine preparation. Virus concentrations provide virus titers of 10 9 ; 10 9 ; 10 8.5 , and 10 9 TCID 50 /ml for O/PanAsia2, A/Iran 05, SAT2/VII/Lib-12 (SAT2/ Lib) and SAT2/VII/Ghb-12(SAT2/Ghb) respectively. # FMD viruses inactivation Complete inactivation 0f the concentrated virus stock using Binary Ethyleneimine (BEI) according to Bahnemann (1975) and Ismail et al.(2013). 1%M BEI in 0.2N NaOH was added to the virus suspension to give a final concentration of 0.001M of BEI. Mixed well the virus and BEI mixture, and the pH then adjusted to 8.0 by sodium bicarbonate. Incubation of the mixture at 37 o C for 12 hours. Sodium thiosulphate added to give a final concentration of 2% to neutralize the BEI action. The inactivated viruses used in the preparation of vaccine formulation with AgNPs, ISA 206 oil, and AgNPs with Montanide ISA 206oil adjuvants for animal immunization. # Silver nanoparticles (AgNPs) characterization Sample of Silver nanoparticles (AgNPs) was prepared as 0.001M/ 10mls and subjected to continuous stirring for 6 hours at room temperature, followed by sonication for three times repeated cycles each of 15 minutes according to Udapudi et al.(2012). # Measuring of Silver nanoparticles (AgNPs) size with Transmission Electron Microscopy (TEM) For transmission electron microscopy of the samples of Silver nanoparticles, prepared by dispersing in ultrapure H 2 O at about 10% concentration and ultrasonicated at 1000L for 15 minutes. One drop of this liquid immediately transferred by a micropipette to a 3 mm diameter Formvar coated copper TEM grid, slowly evaporated to dryness. The samples on the TEM grid analyzed using a 100cx JEOL TEM at 80 kV at CURP, Giza, Egypt. # Silver nanoparticles (AgNPs) cytotoxicity Baby Hamster Kidney cell line used to investigate the adjuvant inhibitory adverse effect on cell proliferation as an indicator of safety to use Silver nanoparticles (AgNPs) as a biocompatible adjuvant in the vaccine formulation. # Montanide ISA 206 The mineral oil-based adjuvant from water-in oilin-water (double emulsion) mixed with antigen w/w supplied by Seppic, Paris, France. # FMD oil adjuvanted vaccine Formulation with oil phase carried out according to the method described by Barnett et al. (2003), and Wael et al. (2014) where the oil phase consisted of Montnide ISA 206 mixed with the inactivated viruses as equal parts of an aqueous and oil phase (w/ w) and mixed thoroughly. # FMD oil and Silver nanoparticles (AgNPs) adjuvanted vaccine The inactivated viruses adjuvanted with ISA 206 oil (w/ w), and AgNPs in a concentration of0.1 mg/dose. # Animalgroups Twelve local breed healthy calves and free from antibodies against FMD viruses as proved by using SNT and ELISA were used in this study where they were divided into four groups (3calves/group) as follow: Group(A): vaccinated with the inactivated polyvalent FMD vaccine adjuvanted with AgNPs vaccine. # Group(B): vaccinated with the inactivated polyvalent FMD vaccine adjuvanted with both oil and AgNPs vaccine. Group (C): vaccinated with the inactivated polyvalent FMD vaccine adjuvanted with oil adjuvant vaccine. # Group (D): was kept none vaccinated as a control group. All vaccinated animals received 3ml/animal of the used vaccine formula inoculated subcutaneously. # Sampling Blood samples were collected from all calf's groups on an anticoagulant for evaluation of cell 2 Year 2020 mediated immunity using Lymphocyte blastogenesis assay on the 3 rd day post-vaccination, then every week up to 10 weeks. Serum samples were collected for the serological tests (SNT and ELISA), weekly for one month then every 2 weeks up to 40 weeks post-vaccination and stored at -20 o C until used. The test was performed by the micro titer technique as described by Ferreira (1976), and the antibody titer expressed as serum neutralization log10. 13. Indirect Enzyme-linked immunosrobent assay (ELISA) It was carried out according to the method described by Voller et al. (1976) and OIE (2012). Serum samples were examined for FMD viral specific IgG antibodies using in-house developed ELISA assay. # III. # Results # a) Confirmation of complete virus inactivation Complete viral inactivation checked by inoculation of BHK cells incubated for two days and compared to the virus-infected cell (virus control) and normal cell (cell control). The inactivated virus showed monolayer of BHK cells and positive control showed viral cytopathic effect at 24-hour post-infection. Complete virus inactivation was obtained by 16hours for O / PanAsia2, A/Iran 05, SAT2/VII/Lib-12 (SAT2/ Lib), and SAT2/VII/Ghb-12(SAT2/Ghb) respectively. # b) Measurement of Silver nanoparticles (AgNPs) size Transmission Electron Microscopy (TEM) showed the particle size of the Silver nanoparticles (AgNPs) adjuvant of 5-10 nm as shown in the photo ( 1) # Photo (1): TEM micrograph of silver nanoparticles c) Testing of adjuvant cytotoxicity The effect of Silver nanoparticles (AgNPs) adjuvant on the in vitro cell proliferation investigated in BHK cell line monolayers after its exposure to gradient concentrations of Silver nanoparticles (AgNPs) for 48 hours. The percentage of viable cells among all of the preparations was above 50% indicating the safety of Silver nanoparticles (AgNPs) adjuvant. # d) In vitro evaluation of cell-mediated immunity using lymphocyte proliferation (XTT) assay The obtained results of cell mediated immune response using lymphocyte proliferation test for all animal groups expressed by Î?"OD (Delta Optical Density) were as follow: Group(A) showed Î?"OD (0.521) by using FMD viruses at 3 rd -day post-vaccination and reached its highest level (1.572) at 3 rd -week post-vaccination, then declined after nine weeks post-vaccination. Group(B) showed Î?"OD (0.566) by using FMD viruses at 3 rdday post-vaccination and reached its highest level (1.660) at 3 rd -week post-vaccination then declined after ten weeks. Group (C) showed Î?"OD (0.486) by using FMD viruses at 3 rd -day post-vaccination and reached its highest level (0.973) at 3 rd -week post-vaccination, then declined after seven weeks. These results are demonstrated in a table (1) and fig (1). 3)it is clear that protective FMD-ELISA antibody titers induced by AgNPs only started at the 1 st week post-vaccination with average values of 1.95, 1.93, 1.82 and 1.82 log 10 for type O, A, SAT2/ Lib and SAT2/Ghb respectively reaching their peak level at the 10 th week post-vaccination with average titers of 3.17, 3.17 Montaind ISA 206 oil vaccine induced FMD ELISA antibody titers started at the 2 nd week postvaccination with average values of 1.93, 1.97, 1.96 and 1.96 log 10 for type O, A, SAT2/ Lib and SAT2/Ghb respectively with peak levels at the10 th week postvaccination with average titers of 3.16, 3.06, 3.14 and 3.12 log10 respectively continued with protective level till the 36 th week then declined as shown in fig (5, 6 & 7). # Delta optical density # Weeks post-vaccination Table (3): FMD ELISA antibody titer in vaccinated calves with the prepared polyvalent FMD vaccine formulae # Group (A) =AgNPs vaccine Group (B) =oil and AgNPs vaccine. # Discssion Nanoparticle-containing vaccines have attracted tremendous interest in recent years, and a wide variety of nanoparticles have been developed and employed as delivery vehicles or immune potentiates, allowing an improvement of antigen stability but also the enhancement of antigen processing and immunogenicity (Smith et al., 2015). The control of FMD in animals was considered to be important to effectively contain the disease in endemic areas so that vaccination of animals is effective in limiting the spread of FMD. So, this study aimed to improve the inactivated polyvalent FMD vaccine by adding Silver nitrate nanoparticles as an adjuvant. Table (1) showed that the results of cellmediated immune response using lymphocyte proliferation test for all animal groups expressed by Î?"OD appeared to be supported by Knudsen et al., (1979) and Sharma et al., (1984) who reported that cell-mediated immune response was a constitute of the immune response against FMD virus, and agreement-in some points with Mercedes et al.(1996) The tabulated results in tables (2 & 3) that SNT and ELISA titers for AgNPs, oil and AgNPs with oil FMD vaccine formulae agreed with Vahid et al. (2016) who showed that adjuvant properties of AgNPs as a potent adjuvant induced higher antibody and the protective function is the production of neutralizing antibodies, either IgM or IgG, which are able to prevent the entry of the virus into cells. The results are supported also by Malyala and Singh (2010) and Rebecca et al. (2010), who found that AgNPs might help the vaccine work more effectively, increasing antibody production, also agreed with Gurunathan et al., (2009); Kaba et al. (2009); Zhao et al. (2014) and Daniel et al. (2019), who found that AgNPs improved B-cells function, mucosal and humoral immunity and protective activity also helped vaccine for induction of strong immunity when used as an adjuvant. The results also go in hand with the results obtained by Hamblin et al. (1986). They explained that the SNT measures those antibodies which neutralize the infectivity of FMD virion, while ELISA probably measures all classes of antibodies even those produced against incomplete and non-infectious virus. Depending on the present obtained results we could conclud that the usage of Silver nitrate nanoparticles (AgNPs) with Montanid ISA 206 oil in inactivated FMD trivalent vaccine induces long-lasting immunity than that induced by oil adjuvant alone and improve both cellular and humoral immunity resulted in earlier and more long-lasting immunity the thing which can aid in companying to control FMD. 8![Preparation of polyvalent FMD formulae: 8.1 FMD Silver nanoparticles (AgNPs) adjuvanted vaccine Silver nanoparticles (AgNPs) were used as 0.1 mg/dose of the polyvalent inactivated FMD virus suspension, according to Vahid et al.(2016).](image-2.png "8 .") 11![In Vitro evaluation of cell-mediated immunity using lymphocyte proliferation (XTT) assay Cell growth and lymphocyte proliferation determined by the colorimetric tetrazolium-derived XTT (sodium 3?-[1-(phenylaminocarbonyl)-3,4-tetrazolium]bis(4-methoxy-6-nitro) benzene sulfonic acid hydrate) assay (Roche Applied Science, Mannheim, Germany) according to Sulic et al. (2005). 12. Serum neutralization test (SNT)](image-3.png "11 .") 1![Fig. (1): Î?"OD in buffy coat in vaccinated calves e) Evaluation of the humeral immune response of calves vaccinated with the prepared FMD vaccine formulae using SNT Table (2) showed that the application of SNT revealed that protective neutralizing serum antibody titer for Silver nitrate AgNPs only started at the 1 st -week postvaccination with average antibody titers of 1.65,1.5,1.5 and 1.5 log 10 for type O,A, SAT2/ Liband SAT2/Ghb respectively. Such antibodies reached their peak level at 10 th -week post-vaccination with average titers of 3.0, 3.0, 2.85 and 2.7 log 10 for the four types respectively and continued as protective levels till the 32 weeks then declined. The protective neutralizing serum antibody titers induced by Montanide ISA 206 oil and AgNPs started at the 2 nd -week post-vaccination with average antibody titers of 1.95,1.8,1.8 and 1.7 log 10 for type O, A, SAT2/ Liband SAT2/Ghb respectively recording their peak level at the 10 th -weeks post-vaccination with average titers of 3.0, 3.0, 2.85 and 2.85 log 10 respectively and continued with protective level till the 40 weeks. FMD serum neutralizing antibody titers induced by Montanide ISA 206 oil started at the 2 nd -week post-](image-4.png "Fig. ( 1") 2![Fig. (2): SNT titer of calve group (A) vaccinated with Silver nitrate FMD vaccine](image-5.png "Fig. ( 2 Fig") ![, 3.14 and 3.14 log 10 for type O, A, SAT2/ Lib and SAT2/Ghb and remained with protective level till the 32 week then declined The protective FMD ELISA antibody titers induced by AgNPs and Montaind ISA 206 oil started at the 2 nd week post-vaccination with average values of 1.98, 1.97, 1.95 and 1.93 log 10 for type O, A, SAT2/ Lib and SAT2/Ghb recording their peak level at the 10 th week post-vaccination with average values of 3.37, 3.32, 3.25 and 3.25 log10 respectively and continued with protective level till the 40 weeks then declined.](image-6.png "") 5![Fig. (5): FMD ELISA antibody titer of calve group (A) vaccinated with Silver nitrate vaccine](image-7.png "Fig. ( 5 Fig") ![; El-Watanyet al.,(1999);Mansour (2001);Samir (2002);Hiam et al.(2010) and Wael et al.,(2014) who found that FMD vaccine stimulated the cellular immune response and lymphocyte stimulation by FMDV were greater than that by mitogens (PHA)with the highest increase in the 1 st and 2 nd weeks post-vaccination, while the present findings disagreed with El-Watany et al., (1999); Mansour (2001) and Sonia et al.(2010) who found that cell-mediated immune response reached its highest level on the 14 th day. Also our results came in agreement with those of Shin et al. (2007) and Frial et al. (2018) who stated that AgNPs act as an activator of the TH1 response. The Th1 type is characterized by the production of antigen-specific IgG2a a Th1 and the secretion of gamma interferon, interleukins which favor cellular immunity. Also these results were in agreement with those of Lázaro et al. (2017), who stated that metallic nanoparticles facilitate the induction of cellular immune response, particularly T-helper 1 and T-helper 17, and their potential functions as adjuvants for subunit vaccines. The obtained results also were supported by Venier et al. (2007); Castellheim et al., (2009); Yen et al. (2009) and Wong et al. (2009), who mentioned that AgNPs enhanced interleukins which enhance cell mediated immune response and nanoparticles are considered an efficient tool for inducing potent immune responses.](image-8.png "") (Time Post-vaccinationÎ?"OD in buffy coat in vaccinated calvesGroup (A)Group (B)Group (C)Group (D)Pre-vaccination0.0560.0420.0460.0523 rd day0. 5210. 5660. 4860.0661week0.8630.8720.4950.0542 week1.4501.6330.9710.0733 week1.5721.6600.9730.0694 week1.2651.4760.7310.0555 week0.8620.9320.6850.0736 week0.6740.8430.6420.0797 week0.6210.8230.5020.0548 week0.5650.7530.4620.0639 week0.5320.7150.3740.06710 week0.4040.6280.3360.056Group (A)= AgNPs vaccine Group (B)= oil and AgNPs vaccine. Group (C)= oil adjuvant vaccine. Group (D)=control group. vaccination with average values of 1.65, 1.5, 1.5 and 1.5with average titers of 2.8, 2.7, 2.7 and 2.5log 10 andlog 10 for type O, A, SAT2/ Lib and SAT2/Ghb respectivelycontinued with protective level till 36 weeks thenreaching their peak level at 10 th -weeks post-vaccinationdeclined as shown in fig (2, 3 & 4).FMD serum neutralizingantibody titer (log10) in vaccinated calve groupsTime post-vaccinationGroup (A)Group (B)Group (C)group DOASAT2 /libSAT2 /GhbOASAT2 / libSAT2/ GhbOASAT2 /libSAT2/ Ghb00.15 0.150.30.30.15 0.150.30.300.30.30.150.151 week1.651.51.51.51. 41.35 1.351.21.21.2 1.050.90.152week1.81.81.71.71.951.81.81.71.651.51.51.50.153 week2.42.252.252.12.42.42.252.251.95 1.95 1.81.80.154 week2.55 2.552.42.252.552.42.252.12.12.22.12.10.456 week2.82.72. 52.52.72.72.552.52.42.25 2.12.10.458 week2.85 2.852.72.552.852.72.72.52.42.42.42.250.4510 week3.03.02.852.73.03.02.852.852.82.72.72.50.4512 week2.852.72.52.42.852.72.52.42.42.42.42.250.3 D D D D14 week2.72.552.42.252.72.52.42.42.252.12.12.10.316 week2.52.552.42.12.52.42.22.252.252.12.12.10.320 week2.52.42.251.952.42.42.12.11.95 1.95 1.81.80.324 week2.252.11.81.652.42.252.12.11.951.81.81.80.328 week1.951.81.651.52.252.11.951.951.81.81.71.70.1532 week1.651.51.51.41.951.81.81.651.65 1.65 1.51.50.1536 week1.41.351.351.21.81.65 1.651.51.651.51.41.50.1540 week1.21.21.050.91.51.51.51.41.35 1.35 1.21.20.15© 2020 Global JournalsGroup (A) Silver nitrateGroup (B) Silver nitrate + Oil Group (C) Oil Group (D) ControlTable (2): FMD serum neutralizing antibody titers in calves vaccinated with inactivated FMD polyvalent Group (A) =AgNPs vaccine Group (B) =oil and AgNPs vaccine. Group (C) =oil vaccine. Group (D) =control group. FMD ELISA antibody titer (log10) of vaccinated calve groupsTime post-Group (A)Group (B)Group (C)vaccinationGroupOASAT2 /libSAT2/GhbOASAT2/ libSAT2/ GhbOASAT2 /libSAT2/GhbD00.210.180.180.270.260.240.220.250.120.280.190.30.61 week1.951.931.821.821.771.731.681.661.551.551.501.500.62week2.182.182.142.141.981.971.951.931.931.971.961.960.63 week2.552.522.542.502.722.702.622.602.192.192.152.130.64 week2.752.702.682.642.852,852.782.762.422.432.402.420.66 week2.872.802.782.702.902.882.882.782.492.482.462.430.758 week2.962.882.802.782.942.982.972.902.862.752.742.730.7510 week 3.173.173.143.143.373.323.253.253.163.063.143.120.7512 week 3.193.173.163.143.253.253.183.182.9 82.952.922.930.914 week 2.862.822,782.762.972.952.842.802.582.572.542.550.916 week 2.742.742.682.732.882.872.842.802.482.452.412.430.920 week 2.522.482.422.372.682.622.632.632.382.362.322.280.624 week 2.352.292.282.272.492.462.442.462.172.142.142.100.628 week 2.152.122.122.102.282.282.252.251.961.931.931.900.632 week 1.941.901.851.842.182.162.152.101.921.901.871.880.336 week 1.731.731.681.621.981.961.961.921.471.421.421.400.340 week 1.641.631.521.521.921951.931.901.421.381.351.350.3 * The pathogenesis and diagnosis of footand mouth disease SAlexandersen ZZhang AIDonaldson AJGarland J Comp Pathol 129 1 2003 * The pathogenesis of foot-and-mouth disease I: viral pathways in cattle JArzt NJuleff ZZhang LLRodriguez TransboundEmerg 58 4 2011 * Binary ethylenimine as an inactivant for foot-and-mouth disease virus and its application for vaccine production HGBahnemann Arch Virol 47 1975 * Foot-and-mouth disease vaccine potency testing: determination and statistical validation of a model using a serological approach PVBarnett RJStatham WVosloo DTHaydon Vaccine 4 23 2003 * First-principles investigation of electrochemical properties of gold nanoparticles J CBatista Ronaldo SMário HMazzoni Chacham 2010 * The history of research in foot and-mouth disease FBrown Virus Res 91 2003 * Innate immune responses to danger signals in systemic inflammatory response syndrome and sepsis ACastellheim OLBrekke TEspevik MHarboe TEMollnes Scand. J Immunol 69 6 2009 * DanielS GPierre LGBerengere VNuria SRemi LBAlice GAlix KBruno CJean MS IgnacioG V Silver Nanoparticle-Adjuvanted Vaccine Protects Against Lethal 2019. 2020 9 * Influenza Infection Through Inducing BALT and IgAmediated Mucosal Immunity. Biomaterials 217 119308 * Relationship between cellular and humoral immunity responses in animal vaccinated with FMD vaccine.Zag HEl-Watany MMShawky OMRoshdy SEl-Kelany LSSN 1110-1458 Vet.J 27 1 1999 * Effect of silver nanoparticles that extracted by Staphylococcus aureuson cellular immunity in rabbits GAFrial ALubna FAyad Al J. Pharm. Sci. & Res 10 6 2018 * ME VFerreira 21/22 Prubade microneutralization poraestudies de anticueropos de la fibreafsta 13th CentropanamericanoFiebreAftosa 1976 * SGurunathan KJLee KKalishwaralal SSheikpranbabu RVaidyanathan SHEom Antiangiogenic properties of silver nanoparticles 2009 30 * Development of novel strategies to control foot-and-mouth disease: marker vaccines and antivirals MJGrubman Biologicals 33 2005 * Foot-and-mouth disease GrubmanMj BBaxt Clin. Microbiol Rev 17 2 2004 * A new enzyme-linked immunosorbent assay (ELISA) for the detection of antibodies against foot-andmouth disease virus. I. Development and method of ELISA CHamblin Barnett RSHedger J Immunol Methods 93 1 1986 * Immunological studies on bivalent foot and mouth disease vaccine using purified and concentrated virus MHiam Fakhry MEman El-Garf J. Egypt. Vet. Med. Asso 70 2010 * Optimization of the Inactivation Process of FMD Virus Serotype SAT-2 by Binary Ethyleneimine (BEI) AHIsmail SAEl-Mahdy WGMossad AbdEl-Krim AS AbouEl-Yazid M AliS M J Vet Adv 201 3 2013 * The effects of nano-silver on the proliferation and cytokine expression by peripheral blood mononuclear cells SHShin MKYe HSKim HSKang Int.Immunopharmacol 7 13 2007 * A nonadjuvanted polypeptide nanoparticle vaccine confers long-lasting protection against rodent malaria SAKaba CBrando QGuo CMittelholzer SRaman DTropel J Immunol 183 2009 * Virus purification RAKillington AStokes JCHierholzer Virology Methods Manual BW JMahy HOKangro New York Academic Press 1996 * Immunity to foot-and-mouth disease virus in guinea pigs: clinical and immune responses RCKnudsen CMGroocock AAAaderson Infection and Immunity 24 1979 * Role of Metallic Nanoparticles in Vaccinology: Implications for Infectious Disease Vaccine Development MMLázaro KAndré PJAna 10.3389/fimmu.2017.00239 Front. Immunol 08 2017 * Polyma transformation hamster cell clones, an investigation of genetic factors affecting cell competence MMacpherson BStocher Virology 16 1962 * Micro/nanoparticle adjuvants: preparation and formulation with antigens PMalyala MSingh Methods in molecular biology 626 2010 * Some studies on the effect of mycotoxins on immune response of FMD vaccinated animals AMansour 2001 Infectious Diseases). Fac.Vet.Med., Cairo University Ph.D. Thesis * Recognition of foot-and-mouth disease virus and its capsid protein VP1 by bovine peripheral T lymphocytes GVMercedes DTimothy CTrevor RMartin EPMichael J Gen Virol 77 1996 * Manual of diagnostic tests and vaccine terrestrial animals. WRLFMD Quarterly Report 2012. April-June 2012 * Persistent Foot-and-Mouth Disease Virus Infection in the Nasopharynx of Cattle; Tissue-Specific Distribution and Local Cytokine Expression JMPacheco GRSmoliga O'Donnell VBrito BPStenfeldt C RodriguezLl JArzt PLoS One 10 5 e0125698 2015 * Biogenic Synthesis of Silver Nanoparticles Capped with L-cysteine SVPerni PHakala Prokopovich Colloids Surf. A 460 2014 * Silver Nanoparticles Interactions with the Immune System: Implications for Health and Disease KRebecca FMRafael MCPaula AnaPaula Z DavidPozo 10.5772/8511Corpus ID: 16094505 2010 * Studies on preparation of newly oil adjuvanted FMD vaccine MA ASamir 2002 Virology) Fac. Vet. Med. Cairo University Ph.D. Thesis * Foot and mouth disease in sheep and goats Sharma Vet. Res. J 4 1 1984. 1981 * Green synthesis of silver nanoparticles using Argimonemexicana leaf extract and evaluation of their antimicrobial activities ASingh DJain MKUpadhyay NKhandelwal HNVerma Digest J. Nanometer. Biostruct 5 2 2010 * JDSmith LDMorton BDUlery Nanoparticles as synthetic vaccines 2015 34 * Comparative study of T cell proliferative response in calves vaccinated with FMD vaccine using Cell titer-Aqueous one solution non radioactive assay (MTS).Zag ASonia Rizk MHiam Abu-Elnaga H IFakhry Vet. J 1110- 1458 38 4 2010 * Drtermination of cell growth and malignant transformation SSulic LPanic LDikic Croat Med. J 46 4 2005 * Synthesis and characterization of Silver nanoparticles BUdapudi PraveenKumar Naik SabihaTabassumSavadatti RupaliSharma SampritaBalgi International Journal of Pharmacy and Biological Sciences 2 2012 * Green synthesis and evaluation of silver nanoparticles as adjuvant in rabies veterinary vaccine AVahid SAlireza BAFahimeh SASadat SMohammad SKAlirezaj BRazieh BRouzbeh RezaA C Int. J Nanomedicine 11 2016 * Innate-immunity cytokines induced by very small size proteoliposomes, a Neisseria-derived Immunological adjuvant CVenier MDGuthmann LEFernandez LFainboim ClinExpImmunol 147 2 2007 * Enzyme immune assay in diagnostic medicine, theory and practice AVoller DEBidwell AnnBartlett Bull. World Health Org 53 1976 * Humeral and cellular immune response of Egyptian trivalent foot and mouth disease oil vaccine in sheep Res. Opin. Anim. Vet. Sci Wael Mossad Gamal El-Din, Ehab El-Sayed Ibrahim, Hind Daoud and Samir Mohamed Ali 4 4 2014 * Further evidence of the anti-inflammatory effects of silver nanoparticles KKWong SOCheung LHuang JNiu CTao CMHo CMChe PKTam Chem. Med. Chem 4 7 2009 * Cytotoxicity and Immunological Response of Gold and Silver Nanoparticles of Different Sizes HJYen SHHsu CLTsai Small 5 13 2009 * Evaluation of the adjuvant effect of silver nanoparticles both in vitro and in vivo YXu HTang JHLiu HWang YLiu ToxicolLett 219 10 2013 * Interleukin-10 production at the early stage of infection with foot-and-mouth disease virus related to the likelihood of persistent infection in cattle ZZhang CDoel BJohn Bashiruddin Vet Res 46 132 2015 * LZhao ASeth NWibowo CZhao Mittern CYu Anton P JMiddelberg Nanoparticle vaccines 2014 32